EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Factor XI Inhibitors in Early Clinical Trials: A Meta-analysis

Mattia Galli iD, Renzo Laborante, Luis Ortega-Paz, Francesco Franchi, Fabiana Rollini, Domenico D'Amario, Davide Capodanno iD, Elena Tremoli, Charles Micheal Gibson, Roxana Mehran, Dominick J Angiolillo iD

Thrombosis and Haemostasis · 2023-06 · 123 (06) · 576-584

DOI: 10.1055/a-2043-0346 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Thrombosis and Haemostasis, online erschienen am 24.03.2023. Verfasst von Mattia Galli und 10 weiteren Autor:innen. Beteiligte Einrichtung: Catholic University of the Sacred Heart, Rome, Italy. Hauptthemen laut MEDLINE: Enoxaparin, Factor XI. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Phase II randomized controlled trials (RCTs) on factor(F)XI inhibitors have shown promising results but they were burdened by low statistical power for clinical outcomes.

Methods

We performed a systematic review and meta-analysis of RCT comparing FXI inhibitors versus other anticoagulants (enoxaparin or direct oral anticoagulants, DOACs) or versus placebo on top of antiplatelet therapy.

Results

Eight RCTs testing FXI inhibitors (ISIS 416858, osocimab, abelacimab, milvexian, asundexian) and enrolling 9,216 patients were included. Compared with enoxaparin, FXI inhibitors were associated with reduced any-bleeding (risk ratio [RR]: 0.49, 95% confidence interval [CI]: 0.31–0.77), no difference in major bleeding (RR: 0.96, 95% CI: 0.41–2.28), and reduced trial-defined efficacy endpoint (RR: 0.62, 95% CI: 0.49–0.79), the latter driven by the high-dose regimens. Compared with DOACs, FXI inhibitors were associated with a trend toward reduced any-bleeding (RR: 0.66, 95% CI: 0.31–1.38) and no difference in major bleeding (RR: 1.03, 95% CI: 0.22–4.78) or in trial-defined efficacy endpoint (RR: 1.23, 95% CI: 0.88–1.70). Compared with placebo, FXI inhibitors were associated with increased any-bleeding (RR: 1.25, 95% CI: 1.08–1.43) and a trend toward increased major bleeding (RR: 1.21, 95% CI: 0.75–1.93), both driven by high-dose regimens, with no difference in trial-defined efficacy endpoint (RR: 1.02, 95% CI: 0.92–1.13).

Conclusion

Results of this meta-analysis on FXI inhibitors suggest increased safety and efficacy compared with enoxaparin and modest increased safety compared with DOACs. The use of FXI inhibitors in adjunct to antiplatelet therapy versus placebo appears to be associated with a dose-dependent increase in bleeding without any difference in efficacy. Study registration This study is registered in PROSPERO (CRD42022367706).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EnoxaparinFactor XIHumansPlatelet Aggregation InhibitorsAnticoagulantsPyrimidinesTriazoles

Substanzen

EnoxaparinFactor XIPlatelet Aggregation InhibitorsAnticoagulantsmilvexianPyrimidinesTriazoles

Autor:innen und Institutionen

  • Catholic University of the Sacred Heart, Rome, Italy.
  • Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.
  • Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States.
  • Dipartimento Universitario di Medicina Traslazionale, Università Piemonte Orientale, Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, Novara, Italy.
  • Division of Cardiology, Azienda Ospedaliero Universitaria Policlinico "G. Rodolico-San Marco," University of Catania, Catania, Italy.
  • Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States.

ORCID-Profile: Mattia Galli, Davide Capodanno, Dominick J Angiolillo

Zitieren

APA

Galli, M., Laborante, R., Ortega-Paz, L., Franchi, F., Rollini, F., D'Amario, D., Capodanno, D., Tremoli, E., Gibson, C. M., Mehran, R., & Angiolillo, D. J. (2023). Factor XI Inhibitors in Early Clinical Trials: A Meta-analysis. Thrombosis and Haemostasis, 123(06), 576-584. https://doi.org/10.1055/a-2043-0346

Vancouver

Galli M, Laborante R, Ortega-Paz L, Franchi F, Rollini F, D'Amario D, et al. Factor XI Inhibitors in Early Clinical Trials: A Meta-analysis. Thrombosis and Haemostasis. 2023;123(06):576-584. doi:10.1055/a-2043-0346

BibTeX
@article{Galli2023,
  author = {Galli, Mattia and Laborante, Renzo and Ortega-Paz, Luis and Franchi, Francesco and Rollini, Fabiana and D'Amario, Domenico and Capodanno, Davide and Tremoli, Elena and Gibson, Charles Micheal and Mehran, Roxana and Angiolillo, Dominick J},
  title = {Factor XI Inhibitors in Early Clinical Trials: A Meta-analysis},
  journal = {Thrombosis and Haemostasis},
  year = {2023},
  volume = {123},
  number = {06},
  pages = {576--584},
  doi = {10.1055/a-2043-0346}
}
Kostenlos starten →